Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 24, 2014

View Archived Issues

Initial report on first-in-human study of 3-V Bioscience's TVB-2640

Valaciclovir approval expanded in Japan

FDA grants orphan drug status to vatiquinone for Rett syndrome

New murine models to study human hepatitis viral infection described at AASLD meeting

Transition Therapeutics reports results from ELND-005 study

Apellis to acquire Potentia Pharmaceuticals

Sanquin and Okklo collaborate to develop cyclodextrins for cardiovascular indications

Karus Therapeutics patents novel HDAC6 inhibitors

Nimbus Apollo reports new ACC2 inhibitors

SOM Biotech and Vall d'Hebron begin trial of repositioned drug for amyloidosis

New GABA(A) receptor agonists disclosed by Sichuan Haisco

MetrioPharm files IND application for immunomodulator MP-1032

A genetically attenuated P. falciparum as vaccine candidate

Cosentyx receives positive CHMP opinion for first-line treatment of psoriasis

Nintedanib obtains positive opinion in European Union for the treatment of IPF

Palovarotene receives EMA orphan medicinal product designation

In vivo protection with inactivated dengue virus antigens plus alphavirus adjuvant

EMA gives positive opinion for hepatitis C therapy Viekirax plus Exviera

Pharmacological profile of a novel PDE10A inhibitor, MT-3014

CHMP adopts positive opinion for Genzyme's Cerdelga

Studies compare time to ESRD in aHUS patients treated with supportive care or eculizumab

Kissei Pharmaceutical discloses new TRPM8 antagonists

Galapagos patents novel CFTR activators

European Commission approves Duaklir Genuair for COPD

CHMP backs Otezla for psoriasis and psoriatic arthritis

Signifor approved in E.U. to treat acromegaly

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...